Study guide
Section 2.8: Applied Pharmacokinetics (PK): One-Compartment Models
Saudi Pharmacist Licensure Examination SPLE - Pharmacist
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
Section 0.1: About the Saudi Pharmacist Licensure Examination (SPLE) Section 0.2: How to Study and Prep for the SPLE
2 Chapter 1: Basic Biomedical Sciences
Section 1.1: Human Physiology & Pathophysiology Foundations Section 1.2: Medical Biochemistry & Enzymology Section 1.3: Medical Microbiology & Immunology Section 1.4: Molecular Genetics & Pharmacogenomics Foundations
3 Chapter 2: Pharmaceutical Sciences
Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR) Section 2.2: Drug ADME (Absorption, Distribution, Metabolism, Excretion) Section 2.3: General Pharmacology: Mechanisms of Drug Action Section 2.4: General Toxicology: Overdose, Antidotes & Adverse Drug Reactions (ADRs) Section 2.5: Pharmacognosy: Natural Products & Dietary Supplements Section 2.6: Basic Pharmaceutics & Dosage Form Design Section 2.7: Biopharmaceutics & Drug Delivery Systems Section 2.8: Applied Pharmacokinetics (PK): One-Compartment Models Section 2.9: Non-linear and Multi-compartment Pharmacokinetics Section 2.10: Sterile Compounding: Techniques & Quality Standards Section 2.11: Non-sterile Compounding & Product Formulation Section 2.12: Pharmaceutical Calculations: Dosing and Strengths Section 2.13: Pharmaceutical Calculations: Dilutions and Reconstitution Section 2.14: Pharmaceutical Calculations: Osmolarity, Milliequivalents, and Alligations
4 Chapter 3: Social, Behavioral, and Administrative Sciences
Section 3.1: Saudi Arabian Healthcare System & Public Health Policies Section 3.2: Pharmacoepidemiology & Post-Marketing Drug Surveillance Section 3.3: Pharmacovigilance & Drug Safety Monitoring in Saudi Arabia Section 3.4: Pharmacoeconomic Principles & Cost-Benefit Analysis Section 3.5: Pharmacy Management, Inventory, and Operations Section 3.6: Saudi Pharmacy Law & SFDA Regulations Section 3.7: Biostatistics, Clinical Trial Design & Literature Evaluation Section 3.8: Professional Ethics, Communication, and Dispensing Systems
5 Chapter 4: Clinical Sciences
Section 4.1: Drug Information Services & Evidence-Based Medicine Section 4.2: Clinical Pharmacokinetics & Therapeutic Drug Monitoring (TDM) Section 4.3: Clinical Pharmacogenomics & Personalized Therapeutics Section 4.4: Disease Prevention, Wellness, and Immunization Schedules Section 4.5: Patient Assessment & Physical Examination Interpretation Section 4.6: Clinical Pharmacology: Cardiovascular Disorders Section 4.7: Clinical Pharmacology: Renal & Urological Disorders Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders Section 4.9: Clinical Pharmacology: Endocrine & Metabolic Disorders Section 4.10: Clinical Pharmacology: Infectious Diseases & Antimicrobial Stewardship Section 4.11: Clinical Pharmacology: Neurological & Psychiatric Disorders Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology Section 4.13: Clinical Pharmacology: Gastrointestinal & Hepatic Disorders Section 4.14: Therapeutic Decision-Making in Special Populations (Geriatrics, Pediatrics, Pregnancy, Lactation)
Section 2.8: Applied Pharmacokinetics (PK): One-Compartment Models
Key Takeaways Explain This Topic AI
The one-compartment open model assumes the body behaves as a single, homogenous unit where drug distribution is instantaneous and rapid equilibrium is established.
The elimination rate constant (Ke) represents the fraction of drug removed per unit time, mathematically defined as Ke = 0.693 / t1/2.
Clearance (Cl) is the theoretical volume of blood cleared of drug per unit time (Cl = Ke * Vd) and determines the maintenance dose rate.
Steady-state concentration (Css) is achieved during continuous infusion when dosing rate equals elimination rate, taking 4 to 5 half-lives to reach.
Therapeutic Drug Monitoring (TDM) of aminoglycosides relies on one-compartment parameters to adjust peak and trough levels to maximize efficacy and minimize toxicity.
Last updated: July 2026
Applied Pharmacokinetics (PK): One-Compartment Models
Pharmacokinetics describes the time course of drug absorption, distribution, metabolism, and excretion (ADME) in the body. The one-compartment open model is the simplest and most clinically utilized model. It views the body as a single, homogeneous unit in which the drug distributes instantly and uniformly upon administration. Although physiological systems are highly complex, this model provides excellent clinical utility for drugs that equilibrate rapidly between blood and tissue spaces, such as aminoglycosides and theophylline.
Assumptions of the One-Compartment Model
Instantaneous Distribution: The drug distributes immediately throughout all tissues and body fluids. There is no delay in reaching equilibrium between plasma and tissues. This is a primary assumption of one-compartment models, simplifying clinical dosage adjustments.
Homogeneity: Plasma concentration is in direct equilibrium with, and proportional to, tissue concentrations at all times.
First-Order Elimination: The rate of drug elimination is directly proportional to the amount remaining in the body. A constant fraction of the drug is eliminated per unit of time.
Open System: The drug is introduced, distributes, and is ultimately eliminated from the compartment via excretion (mainly renal) or metabolism (primarily hepatic), meaning it does not remain in the body indefinitely.
- Core Pharmacokinetic Parameters
- 1. Elimination Rate Constant ( K e K_e K e ) and Half-Life ( t 1 / 2 t_{1/2} t 1/2 )
The elimination rate constant ( K e K_e K e , expressed in hr − 1 \text{hr}^{-1} hr − 1 ) represents the fraction of drug removed from the body per unit of time. Under first-order kinetics, the decline in drug concentration over time is expressed as: C ( t ) = C 0 ⋅ e − K e ⋅ t C(t) = C_0 \cdot e^{-K_e \cdot t} C ( t ) = C 0 ⋅ e − K e ⋅ t
Taking the natural logarithm of both sides yields the linear equation: ln ( C ( t ) ) = ln ( C 0 ) − K e ⋅ t \ln(C(t)) = \ln(C_0) - K_e \cdot t ln ( C ( t )) = ln ( C 0 ) − K e ⋅ t
Graphing concentration versus time on a semi-logarithmic plot yields a straight line with a slope of − K e -K_e − K e .
Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 ): The time required for the plasma concentration to decrease by exactly 50 % 50\% 50% . Setting C ( t ) = C 0 / 2 C(t) = C_0 / 2 C ( t ) = C 0 /2 in the decay equation yields: t 1 / 2 = ln ( 2 ) K e ≈ 0.693 K e t_{1/2} = \frac{\ln(2)}{K_e} \approx \frac{0.693}{K_e} t 1/2 = K e ln ( 2 ) ≈ K e 0.693
2. Volume of Distribution ( V d V_d V d )
The apparent volume of distribution ( V d V_d V d ) relates the amount of drug in the body ( A b A_b A b ) to the measured plasma concentration ( C C C ): V d = A b C V_d = \frac{A_b}{C} V d = C A b
Immediately following an IV bolus dose, before elimination begins: V d = Dose C 0 V_d = \frac{\text{Dose}}{C_0} V d = C 0 Dose
$V_d is a proportionality constant reflecting the extent of drug distribution into tissues.
Small V d V_d V d (e.g., 0.1 L/kg 0.1\text{ L/kg} 0.1 L/kg ): Confined to vascular space (e.g., warfarin).
Large V d V_d V d (e.g., > 5 L/kg >5\text{ L/kg} > 5 L/kg ): Distributes widely into tissues (e.g., digoxin).
3. Clearance ( C l Cl Cl )
Clearance is the volume of plasma cleared of drug per unit of time (expressed in mL/min \text{mL/min} mL/min or L/hr \text{L/hr} L/hr ). It is the most reliable index of drug elimination capacity and is calculated as: C l = K e ⋅ V d Cl = K_e \cdot V_d Cl = K e ⋅ V d
Clearance can also be determined from the Area Under the Curve ( A U C AUC A U C ), which represents total systemic drug exposure: C l = S ⋅ F ⋅ Dose A U C Cl = \frac{S \cdot F \cdot \text{Dose}}{AUC} Cl = A U C S ⋅ F ⋅ Dose
where S S S is the salt fraction and F F F is the bioavailability ( F = 1 F = 1 F = 1 for IV).
4. Continuous IV Infusion & Steady-State ( C s s C_{ss} C ss )
During continuous IV infusion at rate R 0 R_0 R 0 (in mg/hr \text{mg/hr} mg/hr ), drug concentration accumulates until elimination rate equals infusion rate. This plateau is the steady-state concentration ( C s s C_{ss} C ss ): C s s = R 0 C l C_{ss} = \frac{R_0}{Cl} C ss = Cl R 0
The time to reach C s s C_{ss} C ss is governed solely by the drug's half-life ( t 1 / 2 t_{1/2} t 1/2 ), taking 4 to 5 half-lives of constant dosing.
5. Multiple IV Bolus Dosing
During multiple dosing at interval τ \tau τ , peak ( C m a x , s s C_{max, ss} C ma x , ss ) and trough ( C m i n , s s C_{min, ss} C min , ss ) steady-state concentrations are: C m a x , s s = Dose / V d 1 − e − K e ⋅ τ C_{max, ss} = \frac{\text{Dose} / V_d}{1 - e^{-K_e \cdot \tau}} C ma x , ss = 1 − e − K e ⋅ τ Dose / V d C m i n , s s = C m a x , s s ⋅ e − K e ⋅ τ C_{min, ss} = C_{max, ss} \cdot e^{-K_e \cdot \tau} C min , ss = C ma x , ss ⋅ e − K e ⋅ τ
Pharmacokinetic Parameter Reference Table
Parameter Abbreviation Common Units Key Equations Clinical Application
Half-Life t 1 / 2 t_{1/2} t 1/2 hours (hr) \text{hours (hr)} hours (hr) t 1 / 2 = 0.693 / K e t_{1/2} = 0.693 / K_e t 1/2 = 0.693/ K e Determines dosing frequency and time to steady state.
Elimination Constant K e K_e K e hr − 1 \text{hr}^{-1} hr − 1 K e = C l / V d K_e = Cl / V_d K e = Cl / V d Represents the fraction of drug eliminated per hour.
Volume of Distribution V d V_d V d L \text{L} L or L/kg \text{L/kg} L/kg V d = Dose / C 0 V_d = \text{Dose} / C_0 V d = Dose / C 0 Used to calculate loading doses.
Clearance C l Cl Cl L/hr \text{L/hr} L/hr or mL/min \text{mL/min} mL/min C l = K e ⋅ V d Cl = K_e \cdot V_d Cl = K e ⋅ V d Determines maintenance doses.
Area Under the Curve A U C AUC A U C mg ⋅ hr/L \text{mg} \cdot \text{hr/L} mg ⋅ hr/L A U C = Dose / C l AUC = \text{Dose} / Cl A U C = Dose / Cl Measures total drug exposure.
Step-by-Step Worked Clinical Example
A 65-year-old male patient weighing 80 kg 80\text{ kg} 80 kg is prescribed Gentamicin. His serum creatinine is 1.2 mg/dL 1.2\text{ mg/dL} 1.2 mg/dL . Calculate the parameters and dose to achieve target peak ( C m a x C_{max} C ma x ) 8 mcg/mL 8\text{ mcg/mL} 8 mcg/mL and trough ( C m i n C_{min} C min ) < 1 mcg/mL <1\text{ mcg/mL} < 1 mcg/mL at a 24 24 24 -hour dosing interval ( τ = 24 hr \tau = 24\text{ hr} τ = 24 hr ).
Step 1: Calculate Creatinine Clearance (CrCl) CrCl = ( 140 − 65 ) ⋅ 80 72 ⋅ 1.2 ≈ 69.4 mL/min ≈ 4.16 L/hr \text{CrCl} = \frac{(140 - 65) \cdot 80}{72 \cdot 1.2} \approx 69.4\text{ mL/min} \approx 4.16\text{ L/hr} CrCl = 72 ⋅ 1.2 ( 140 − 65 ) ⋅ 80 ≈ 69.4 mL/min ≈ 4.16 L/hr
Step 2: Estimate Volume of Distribution ( V d V_d V d ) and Elimination Constant ( K e K_e K e )
Using aminoglycoside average V d V_d V d of 0.25 L/kg 0.25\text{ L/kg} 0.25 L/kg of body weight: V d = 0.25 ⋅ 80 = 20 L V_d = 0.25 \cdot 80 = 20\text{ L} V d = 0.25 ⋅ 80 = 20 L K e = C l V d = 4.16 L/hr 20 L = 0.208 hr − 1 K_e = \frac{Cl}{V_d} = \frac{4.16\text{ L/hr}}{20\text{ L}} = 0.208\text{ hr}^{-1} K e = V d Cl = 20 L 4.16 L/hr = 0.208 hr − 1
Step 3: Determine Dose and Verify Trough Dose = C m a x ⋅ V d = 8 mg/L ⋅ 20 L = 160 mg \text{Dose} = C_{max} \cdot V_d = 8\text{ mg/L} \cdot 20\text{ L} = 160\text{ mg} Dose = C ma x ⋅ V d = 8 mg/L ⋅ 20 L = 160 mg C ( 24 ) = 8 mg/L ⋅ e − 0.208 ⋅ 24 ≈ 0.05 mcg/mL C(24) = 8\text{ mg/L} \cdot e^{-0.208 \cdot 24} \approx 0.05\text{ mcg/mL} C ( 24 ) = 8 mg/L ⋅ e − 0.208 ⋅ 24 ≈ 0.05 mcg/mL
This trough is safe ( < 1 mcg/mL <1\text{ mcg/mL} < 1 mcg/mL ), making 160 mg 160\text{ mg} 160 mg IV every 24 hours 24\text{ hours} 24 hours appropriate.